CRISPR/Cas9 genome editing in human hematopoietic stem cells

Area of Science:

• Biotechnology
• Molecular Biology
• Hematology

Background:

• Homologous recombination (HR) gene targeting in human hematopoietic stem cells (HSCs) is crucial for understanding gene function and developing curative therapies.
• Existing protocols for HR targeting in HSCs lack comprehensiveness and reproducibility.
• Precise genetic modification of HSCs is essential for treating hematological diseases.

Purpose of the Study:

• To establish a detailed, reproducible protocol for HR-mediated genome editing in HSCs.
• To combine CRISPR/Cas9 technology with rAAV6 and flow cytometry for efficient HSC targeting.
• To enable precise genetic modifications in HSCs for research and therapeutic applications.

Main Methods:

• Development of a protocol for producing, enriching, and analyzing HR-targeted HSCs.
• Utilized CRISPR/Cas9 gene editing technology.
• Incorporated adeno-associated virus serotype 6 (rAAV6) and flow cytometry for targeting and enrichment.
• Included in vitro and in vivo analyses for validation.

Main Results:

• Successfully demonstrated precise introduction of single-nucleotide changes and gene cassettes into HSCs.
• Protocol allows for streamlined genome editing at any locus of interest.
• In vitro analyses completed in 3 weeks; in vivo engraftment analyses in 16 weeks.
• Provided troubleshooting and optimization guidelines.

Conclusions:

• The developed protocol offers a comprehensive and reproducible method for HR-mediated genome editing in HSCs.
• This technique facilitates gene function investigations during hematopoiesis.
• The protocol holds significant potential for HSC transplantation-based therapies, including correction of genetic mutations for sickle cell disease, β-thalassemia, and primary immunodeficiencies.